“The Company is adhering to a value-building strategy born from discussions with larger pharmaceutical companies interested in Kevetrin, one of the world’s most advanced p53 drug candidates. Securing the right development partner for Kevetrin remains an important objective.”
That should explain it all. IPIX is looking to see who fits the slipper.
Targeting specific genes are getting a lot of attention and the fda loves it! Kevetrin Oral is our shot!
News 
Market Data 
Discover 
AI
